Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | MOK | Q9UQ07 | 5/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336361 | 0.92 | MOK (0.51) | PIK3CAMOKGRM4 | |
| SCHEMBL3339979 | 0.88 | KIT (0.48) | MAPK14MAPK13MAPK12MAPK11PIK3CA | |
| SCHEMBL5127444 | 0.85 | AVPR1B (0.39) | MAPK14MAPK13MAPK12MAPK11PIK3CA | |
| SCHEMBL3335706 | 0.83 | NAMPT (0.42) | MAPK14MAPK13MAPK12MAPK11PIK3CA | |
| SCHEMBL5146071 | 0.82 | MAP3K11 (0.45) | MAPK14MAPK13MAPK12MAPK11PIK3CA | |
| SCHEMBL3339873 | 0.82 | MOK (0.50) | PIK3CAMOKGRM4 | |
| SCHEMBL3336253 | 0.82 | PTGS1 (0.42) | PIK3CAADORA2AADORA1 | |
| SCHEMBL3334852 | 0.82 | MAPK14 (0.41) | MAPK14PIK3CAADORA2A | |
| SCHEMBL3334174 | 0.81 | ADORA2A (0.54) | MAPK14MAPK13MAPK12MAPK11PIK3CA | |
| SCHEMBL3335675 | 0.81 | MAPT (0.41) | PIK3CAADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | claimed |
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | OPRD1, IFNAR1, NR4A1 | MAPK14 2920/4885MAPK13 2635/4885MAPK12 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.